Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623215 | 0.88 | SCN9A (0.39) | SCN9AADRB3ADRB1SCN5AADRB2 | |
| SCHEMBL1622237 | 0.87 | SCN9A (0.40) | SCN9AADRB3ADRB1SCN5AADRB2 | |
| SCHEMBL1620612 | 0.83 | SCN9A (0.40) | SCN9AADRB3SCN5A | |
| SCHEMBL1622644 | 0.83 | BCL2L1 (0.36) | SCN9AADRB3ADRB1 | |
| SCHEMBL4585947 | 0.82 | SCN9A (0.56) | SCN9AADRB3ADRB1ADRB2 | |
| SCHEMBL1623311 | 0.81 | ADRB3 (0.44) | SCN9AADRB3ADRB1SCN5APDE4A | |
| SCHEMBL1620530 | 0.75 | ADRB3 (0.35) | ADRB3ADRB1 | |
| SCHEMBL1621085 | 0.73 | PDE5A (0.47) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL29958023 | 0.72 | PDE4A (0.44) | ADRB3ADRB1ADRB2PDE4APDE4B | |
| SCHEMBL1622410 | 0.72 | ADRB3 (0.36) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928264-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2011-04-19 | — | — | US | disclosed |
| EP-1791811-B1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2009-12-23 | — | — | EP | disclosed |
| US-20080039506-A1 | Aminoalcohol Derivatives | ASTELLAS PHARMA INC. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1791811-A1 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006033446-A1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039506-A1 | Aminoalcohol Derivatives | HRH4, HRH2, CBR3 | SCN9A 1123/4885ADRB3 40/4885ADRB1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.